X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare VENUS REMEDIES with Cadila Healthcare - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs CADILA HEALTHCARE - Comparison Results

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES CADILA HEALTHCARE VENUS REMEDIES/
CADILA HEALTHCARE
 
P/E (TTM) x -3.7 18.1 - View Chart
P/BV x 0.1 4.1 3.4% View Chart
Dividend Yield % 0.0 1.0 -  

Financials

 VENUS REMEDIES   CADILA HEALTHCARE
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-18
CADILA HEALTHCARE
Mar-18
VENUS REMEDIES/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs126558 22.6%   
Low Rs61362 16.9%   
Sales per share (Unadj.) Rs301.8116.3 259.5%  
Earnings per share (Unadj.) Rs-24.917.9 -139.2%  
Cash flow per share (Unadj.) Rs2.523.1 11.0%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.8 0.0%  
Book value per share (Unadj.) Rs293.385.4 343.4%  
Shares outstanding (eoy) m12.341,023.74 1.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.34.0 7.8%   
Avg P/E ratio x-3.825.7 -14.6%  
P/CF ratio (eoy) x36.719.9 184.9%  
Price / Book Value ratio x0.35.4 5.9%  
Dividend payout %019.6 0.0%   
Avg Mkt Cap Rs m1,154470,664 0.2%   
No. of employees `0000.911.8 7.8%   
Total wages/salary Rs m39318,545 2.1%   
Avg. sales/employee Rs Th4,026.110,072.7 40.0%   
Avg. wages/employee Rs Th425.01,569.1 27.1%   
Avg. net profit/employee Rs Th-331.81,547.7 -21.4%   
INCOME DATA
Net Sales Rs m3,724119,049 3.1%  
Other income Rs m231,132 2.0%   
Total revenues Rs m3,747120,181 3.1%   
Gross profit Rs m39528,475 1.4%  
Depreciation Rs m3385,388 6.3%   
Interest Rs m354911 38.9%   
Profit before tax Rs m-27523,308 -1.2%   
Minority Interest Rs m0628 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m325,644 0.6%   
Profit after tax Rs m-30718,292 -1.7%  
Gross profit margin %10.623.9 44.3%  
Effective tax rate %-11.524.2 -47.4%   
Net profit margin %-8.215.4 -53.6%  
BALANCE SHEET DATA
Current assets Rs m2,63882,005 3.2%   
Current liabilities Rs m2,30560,720 3.8%   
Net working cap to sales %8.917.9 50.0%  
Current ratio x1.11.4 84.7%  
Inventory Days Days13573 185.2%  
Debtors Days Days4698 47.1%  
Net fixed assets Rs m4,87183,703 5.8%   
Share capital Rs m1231,024 12.1%   
"Free" reserves Rs m3,49686,421 4.0%   
Net worth Rs m3,61987,445 4.1%   
Long term debt Rs m1,37425,551 5.4%   
Total assets Rs m7,509180,653 4.2%  
Interest coverage x0.226.6 0.8%   
Debt to equity ratio x0.40.3 130.0%  
Sales to assets ratio x0.50.7 75.3%   
Return on assets %0.610.6 5.9%  
Return on equity %-8.520.9 -40.5%  
Return on capital %1.622.0 7.2%  
Exports to sales %00-   
Imports to sales %13.90-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs m517NA-   
Fx inflow Rs m042,683 0.0%   
Fx outflow Rs m51711,242 4.6%   
Net fx Rs m-51731,441 -1.6%   
CASH FLOW
From Operations Rs m5149,193 5.6%  
From Investments Rs m-123-9,737 1.3%  
From Financial Activity Rs m-387515 -75.2%  
Net Cashflow Rs m4-29 -14.5%  

Share Holding

Indian Promoters % 32.9 74.8 43.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 0.2 8.3 2.2%  
FIIs % 0.6 5.9 9.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 66.4 11.0 603.6%  
Shareholders   20,121 44,069 45.7%  
Pledged promoter(s) holding % 36.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT LTD.  GSK PHARMA  PANACEA BIOTECH  

Compare VENUS REMEDIES With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Prepare to Ride Out Volatile Markets with Rahul Shah(Podcast)

Watching the stock market basically volatile on a regular basis isn't easy. Catch Rahul Shah talk about his mantra to ride out the volatility in times like these.

Related Views on News

VENUS REMEDIES Announces Quarterly Results (2QFY19); Net Profit Down 16.3% (Quarterly Result Update)

Nov 23, 2018 | Updated on Nov 23, 2018

For the quarter ended September 2018, VENUS REMEDIES has posted a net profit of Rs 8 m (down 16.3% YoY). Sales on the other hand came in at Rs 809 m (down 10.6% YoY). Read on for a complete analysis of VENUS REMEDIES's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (2QFY19); Net Profit Down 18.6% (Quarterly Result Update)

Nov 5, 2018 | Updated on Nov 5, 2018

For the quarter ended September 2018, CADILA HEALTHCARE has posted a net profit of Rs 4 bn (down 18.6% YoY). Sales on the other hand came in at Rs 30 bn (down 8.4% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My Top 7 Stocks to Buy Now(The 5 Minute Wrapup)

Nov 30, 2018

Of all the stocks that you could buy in this market, I've picked the seven best safe stocks that offer the ideal combination of safety and profit.

4 Rebound Stocks to Profit from the Current Small Cap Crash(Profit Hunter)

Dec 3, 2018

Indian small cap space is offering a discount season. Make sure you do not get too late to scoop up the bargains.

Reliance CPSE ETF (FFO3): Should You Invest?(Outside View)

Nov 29, 2018

Personalfn's analysis note on Reliance Mutual Fund Central Public Sector Enterprises Exchange Traded Fund (CPSE ETF). Should you subscribe?

Safety Beats Growth in 2018(Chart Of The Day)

Nov 30, 2018

With the markets turning up, these are my top 7 stock picks.

Why Qualitative Aspects Are So Important To Pick Mutual Funds(Outside View)

Nov 26, 2018

PersonalFN briefly outlines why qualitative parameters are equally important in selecting mutual funds.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

VENUS REMEDIES SHARE PRICE


Dec 7, 2018 (Close)

TRACK VENUS REMEDIES

  • Track your investment in VENUS REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON VENUS REMEDIES

VENUS REMEDIES 8-QTR ANALYSIS

COMPARE VENUS REMEDIES WITH

MARKET STATS